We designed the current randomized multicenter trial to assess whether standard care plus albumin therapy will increase the proportion of clinically stable patients at day 5 of admission compared to standard care alone in patients with CAP and hypoalbuminemia. The gene discussed is ALB; the disease is Hypoalbuminemia.